Retatrutide vs Thymalin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Thymalin
Thymalin is a polypeptide preparation derived from calf thymus. Developed in Russia, it has been used for decades to support immune function and has shown potential anti-aging effects in long-term studies.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Thymalin |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Regulates the ratio of T-cell subpopulations, stimulates cellular immunity, and enhances phagocytosis. Also affects neuroendocrine regulation and may influence melatonin production. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Clinical protocols: 5-20mg daily intramuscularly for 3-10 days. Often cycled 1-2 times per year for maintenance. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Intramuscular injection. Usually administered in short courses rather than continuously. Often combined with Epithalamin for anti-aging protocols. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Generally well-tolerated. May cause injection site reactions or temporary flu-like symptoms as immune function is modulated. |
| Best For |